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Article focus
  This study investigated the effects of 
tranexamic acid (TXA) toxicity on human 
periarticular tissues including tendon, 
synovium, and cartilage.
Key messages
  TXA caused significant periarticular tissue 
toxicity ex vivo and in vitro at commonly 
used clinical concentrations.
  We suggest clinicians show caution when 
considering topical TXA treatments, par­
ticularly on soft­tissue orthopaedic pro­ 
 cedures.
  Further human clinical trials are required 
to confirm the safety of TXA before it can 
be recommended for standard topical 
practice.
Strengths and limitations
  While our study shows increased cell 
death, this may not necessarily translate 
into poor clinical outcomes to the patient 
and we recognize that studies evaluating 
early and longer­term clinical follow­up 
of topical TXA are required.
Introduction
Surgeons continually strive to improve post­
procedural rehabilitation in their patients, with 
the hope and intention of enhancing patient 
satisfaction and surgical outcomes. one such 
area that has been targeted across the surgical 
specialties is intra­ and post operative blood 
loss.1 Within orthopaedic surgery, this is par­
ticularly relevant in patients undergoing hip 
and knee arthroplasty, commonly performed 
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Objectives
Tranexamic acid (TXA) is an anti-fibrinolytic medication commonly used to reduce peri-
operative bleeding. Increasingly, topical administration as an intra-articular injection or 
perioperative wash is being administered during surgery. Adult soft tissues have a poor 
regenerative capacity and therefore damage to these tissues can be harmful to the patient. 
This study investigated the effects of TXA on human periarticular tissues and primary cell 
cultures using clinically relevant concentrations.
Methods
Tendon, synovium, and cartilage obtained from routine orthopaedic surgeries were used for 
ex vivo and in vitro studies using various concentrations of TXA. The in vitro effect of TXA on 
primary cultured tenocytes, fibroblast-like synoviocytes, and chondrocytes was investigated 
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability 
assays, fluorescent microscopy, and multi-protein apoptotic arrays for cell death.
Results
There was a significant (p < 0.01) increase in cell death within all tissue explants treated 
with 100 mg/ml TXA. MTT assays revealed a significant (p < 0.05) decrease in cell viability 
in all tissues following treatment with 50 mg/ml or 100 mg/ml of TXA within four hours. 
There was a significant (p < 0.05) increase in cell apoptosis after one hour of exposure to TXA 
(100 mg/ml) in all tissues.
Conclusion
The current study demonstrates that TXA caused significant periarticular tissue toxicity 
ex vivo and in vitro at commonly used clinical concentrations.
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procedures that are frequently associated with considera­
ble blood loss.2 Postoperative anaemia may predispose 
patients to an increased risk of cardiopulmonary events 
and adverse transfusion reactions,3 while prolonged hos­
pitalization associated with significant blood loss may 
result in an increased risk of hospital­acquired infec­
tions.4,5 Ultimately, there may be delayed patient rehabili­
tation and an escalation in healthcare costs.
Activation of fibrinolysis during and after surgery is a 
phenomenon considered to contribute significantly to 
intra­ and postoperative blood loss.6 Intravenous (Iv) 
administration of the anti­fibrinolytic agent (TXA) is an 
established off­licence perioperative haemostatic treat­
ment.7 Tranexamic acid is a synthetic derivative of the amino 
acid lysine that inhibits fibrinolysis by competitively blocking 
the lysine binding site on plasminogen and subsequently 
inhibiting its conversion to plasmin, a fibrinolytic protease 
that degrades fibrin clots. It has been shown to reduce post­
operative bleeding and blood transfusion requirements in 
patients undergoing hip and knee arthroplasty.3,8 Despite its 
proven benefits, concern remains about the safety of its 
intravenous administration, given the documented risk of 
thromboembolic events and acute renal impairment.3,9
In view of the safety concerns relating to the intrave­
nous administration of TXA, it has been hypothesized that 
topical administration (intra­/periarticular) may avoid the 
risks of systemic administration. Recent randomized con­
trolled trials investigating topical administration during 
hip and knee arthroplasty have demonstrated significantly 
lower blood loss and transfusion rates in comparison with 
control groups with no apparent significant systemic side 
effects.10,11 Topical TXA solution concentrations have 
ranged from 10 mg/ml to 200 mg/ml, with application 
strategies varying between studies.3 Most topical adminis­
tration studies to date have focused primarily on hip and 
knee arthroplasty, although it is becoming increasingly 
popular during soft­tissue reconstructions such as anterior 
cruciate ligament (ACl) reconstruction.12 However, unlike 
the majority of hip and knee arthroplasties, this involves 
the direct exposure of healthy cartilage, tendon, and liga­
ment to TXA. At present, the interaction between these 
important periarticular tissues and TXA remains largely 
unknown, with rodent and human in vitro studies on 
chondrocytes providing conflicting results.13­17 Adult ten­
don and, in particular, cartilage have a poor regenerative 
capacity and therefore significant damage to these tissues 
may be devastating to the patient.18,19
This study was designed to test the hypothesis that 
TXA had no cytotoxic effects on human periarticular tis­
sues including tendon, synovium, and cartilage.
Materials and Methods
Study design. All procedures and protocols were approved 
by the Ethics Committee under approval number REC14/
WS/1035 with informed consent obtained and carried out 
in accordance with standard operative procedures.
tissue collection and preparation. Human tendon tissue 
was harvested during hamstring tendon ACl. Synovial 
tissue was harvested during total hip arthroplasty (THA) 
or total knee arthroplasty (TKA). Cartilage tissue was har­
vested from femoral heads obtained during hip hemi­
arthoplasty for femoral neck fracture. Tissues were then 
separated for either ex vivo or in vitro experiments as out­
lined below. All patients were screened and excluded if 
there was a prior history of surgery affecting the same 
joint, malignancy, or infection. Cartilage was excluded 
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Tranexamic acid (TXA) toxicity in periarticular tissues ex vivo. a) Percentage of dead cells in control (0 mg/ml) and TXA­treated (100 mg/ml) cells in each periarticu­
lar tissue (n = 3 tendon, synovium; n = 4 cartilage) after 16 hours of treatment. Mean ± standard error of the mean; Student’s paired t­test. †p < 0.01. b) Tendon, 
synovium, ligament, and cartilage tissue imaged by confocal microscopy with 5­chloromethylfluorescein diacetate (CMFDA) and propidium iodide (PI) stain at 
16 hours of treatment in control and TXA­treated (100 mg/ml TXA cells). Green stained cells counted as live and red stained cells counted as dead.
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if there was any macroscopic evidence of osteoarthritis, 
and only outerbridge grade 0 cartilage was used.20
tissue culture. Human tendon­derived tenocytes were 
explanted from hamstring tendons and fibroblast­like 
synoviocytes (FlS) from synovial tissue, as described 
previously.21 Cultures were maintained in a humidified 
environment at 37°C, 5% Co2 in Roswell Park Memorial 
Institute (RPMI) 1640, supplemented with 10% foetal 
bovine serum (FBS), 1% penicillin­streptomyocin, and 
l­glutamine (life Technologies). Cells were grown to 
subconfluency and passaged using trypsin ethylenedi­
aminetetraacetic acid (EDTA) (Sigma­Aldrich, Gillingham, 
United Kingdom). Cells from the third and fourth pas­
sages were seeded two days prior to experimentation 
and no phenotypic drift was confirmed using polymerase 
chain reaction (PCR; Scleraxis, Aggregan, SoX9 genes).
Human chondrocytes were isolated by enzymatic 
digestion of intact femoral head articular cartilage.22 
Chondrocytes were maintained in Dulbecco's modified 
Eagle's medium (DMEM), supplemented with 10% FBS, 
1% penicillin­streptomycin, 1% amphotericin, and 10% 
4­(2­hydroxyethyl)­1­piperazineethanesulfonic acid (HEPES). 
Cells were grown to subconfluency and detached for 
seeding using Accutase (Sigma­Aldrich). Cells from the 
initial explantation were not passaged. They were seeded 
two days prior to experimentation. Tranexamic acid was 
added to concentrations of 0 mg/ml, 1 mg/ml, 50 mg/ml, 
or 100 mg/ml. Dilution groups were pH­monitored to 
ensure effects were not related to acidity.
Confocal microscopy. Tissue samples were cut into 1 cm2 
quadruplicate replicate pieces and treated with 0 mg/ml 
or 100 mg/ml TXA in RPMI, supplemented with 10% 
FBS and 1% penicillin­streptomycin, at 37°C and 5% 
Co2 for 16 hours. They were then washed in RPMI and 
stained with 12.5 µM 5­chloromethylfluorescein diacetate 
(CMFDA) and 10 μMl propidium iodide23 for two hours at 
37°C, then fixed in 4% formaldehyde. They were imaged 
using confocal microscopy (lSM 800; Zeiss, Cambridge, 
United Kingdom), and the proportion of live (green) and 
dead (red) cells was counted using Imaris x64 (8.4.1) soft­
ware (Bitplane ltd, Zurich, Switzerland). Three individual 
donor tissues were used for the tendon and synovium, 
and four donors were used for the cartilage tissue.
Cell viability assays. The in vitro effect of TXA at concen­
trations of 0 mg/ml, 1 mg/ml, 50 mg/ml, and 100 mg/ml 
over 1, 4, and 24 hours on primary human cell cultures 
was determined using 3­(4,5­dimethylthiazol­2­yl)­
2,5­diphenyltetrazolium bromide (MTT) cell viability 
assays (Sigma­Aldrich). 2.5 × 104 cells were seeded in 
each well of a 12­well plate in a volume of 500 μl media 
per well. once attached, cells were treated with TXA. 
Culture medium was aspirated, and sterile­filtered MTT 
was added to each well. Cells were washed with phos­
phate­buffered saline (PBS) and incubated with dimethyl 
sulfoxide (DMSo) for ten minutes to dissolve the forma­
zan product. This was then transferred into a 96­well 
plate (100 μl per well in duplicate) and read on a micro­
plate reader at 540 nm.
Mitochondrial membrane potential assays. The mito­
chondrial membrane potential was measured accord­
ing to the manufacturer’s instructions (DePsipher; 
R&D Systems, Inc., Minneapolis, Minnesota) by fluo­
rescent microscopy using a fluorescent cationic dye, 
5,5′,6,6′­tetrachloro­1,1′,3,3′­tetraethylbenzimidazolyl
carbocyanine iodide (JC­1). 5 ×104 cells/well were cul­
tured in 12­well plates for 48 hours in the presence of 
increasing concentrations of TXA with medium (0 mg/ml, 
1 mg/ml, 50 mg/ml, or 100 mg/ml). The cells were then 
washed with PBS, and reaction buffer was added with 
DePsipher (5 µl per sample) and stabilizer solution. The 
cells were incubated at room temperature, in the dark, 
for a minimum of 15 minutes. The cells were analyzed 
within one hour by fluorescent microscopy using a fluo­
rescein long­pass filter (EvoS Fl Auto 2 Imaging System; 
Thermo Fisher Scientific, Waltham, Massachusetts). 
Using this system, cells undergoing apoptosis should 
appear green (585/590 nm), while healthy cells appear 
red (510/527  nm). Four corner random field images 
were saved and the number of apoptotic (green) and live 
(red) cells counted per image. The percentage of apop­
totic cells as a proportion of total cells was calculated 
for each image and the mean percentage calculated for 
each sample.
Cellular apoptosis. Multi­apoptotic protein detection arrays 
(Human Apoptosis Antibody Array Kit; R&D Systems, Inc.) 
were used to determine possible apoptotic pathways 
involved in cell death according to the manufacturer’s 
instructions. Cells were treated with 0 mg/ml, 1 mg/ml, 
50 mg/ml, or 100 mg/ml TXA for one hour. The protein 
content of each well was quantified using a Micro bicin­
choninic acid assay (BCA) Protein Assay Kit (Thermo Fisher 
Scientific) and read on a microplate reader at 540  nm. 
lysate protein concentrations were then normalized 
in lysis buffer. Cells were cultured in 12­well plates for 
one hour, with increasing concentrations of TXA with 
medium (0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml). 
Cell supernatants were aspirated and discarded. After 
blocking of non­specific binding at room temperature 
for one hour, antibody array membranes were incu­
bated with the cell lysate (1.5 ml) at 4°C overnight and 
then with a diluted solution of horseradish peroxidase 
(HRP)­conjugated streptavidin at room temperature for 
30 minutes. visualization of protein expression was car­
ried out by chemiluminescence and signal intensity was 
table I. Numerical representation of the data shown in Figure 1
0 mg/ml 100 mg/ml p-value
 Mean (sd) n Mean (sd) n  
Cartilage 5.5 (4.1) 4 65.0 (14.3) 4 0.005
Tendon 65.0 (4.5) 3 96.3 (3.2) 3 0.002
Synovium 18.0 (11.1) 3 66.0 (1.0) 3 0.02
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quantified using luminex (Azure c500; Azure Biosystems, 
Dublin, California). The immunoreactive band density 
was analyzed using WinImage studio version 5.2 (lI­CoR 
Biosciences, lincoln, Nebraska).
Statistical analysis. All results are shown as mean ± stan­
dard error of the mean, and all statistical analysis was 
performed using Student’s paired t­test or analysis of 
variance (ANovA) test with Dunnett’s post hoc  analysis, 
as shown in the figures, using the GraphPad Prism 5 
software (GraphPad Software, San Diego, California). A 
p­value of < 0.05 was considered statistically significant.
Results
tranexamic acid toxicity in periarticular tissues ex vivo. We 
first investigated whether ex vivo tissues (n = 3 tendon, 
synovium; n = 4 cartilage) treated with TXA displayed 
evidence of cytotoxicity. Treatment with 100  mg/ml of 
TXA for 16 hours caused a significant increase in cell 
death within tendon, synovium, and cartilage tissues 
compared with control (Fig. 1 and Table I).
tranexamic acid toxicity in vitro. Following ex vivo experi­
ments, we performed time and dose curves to determine 
the concentration and duration of exposure to TXA at 
which a significant reduction in cell viability occurred. 
MTT assays measuring cell metabolic activity acted as an 
indirect measurement of cell viability. A significant fall in 
cell viability occurred in all cell types at higher doses over 
a four­hour duration or low concentrations following 24 
hours of treatment.
Tenocyte viability was significantly reduced when 
treated with TXA at 100 mg/ml for four hours (Fig. 2). 
Additionally, concentrations of 1 mg/ml, 50 mg/ml, or 
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Tranexamic acid (TXA) toxicity in vitro. 3­(4,5­dimethylthiazol­2­yl)­2,5­diphenyltetrazolium bromide (MTT) assay of: a) to c) tenocyte (n = 11); d) to f) fibroblast­
like synoviocyte (FlS; n = 5); and g) to i) chondrocyte (n = 5) viability at: a), d), g) one; b), e), h) four; and c), f), i) 24 hours. values were measured as lumi­
nescence and expressed as percentage change from untreated (control) wells. *p < 0.05; †p < 0.01; ‡p < 0.001. Data are means ± standard error of the mean; 
one­way analysis of variance; Dunnett’s Multiple Comparison Test.
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100 mg/ml of TXA for 24 hours also caused a significant 
reduction in cell viability. Fibroblast­like synoviocyte 
viability was significantly reduced when treated with 
TXA at 1 mg/ml, 50 mg/ml, or 100 mg/ml for four hours 
and 50 mg/ml or 100 mg/ml for 24 hours (Fig. 2). 
Furthermore, chondrocyte viability was significantly 
reduced when treated with TXA at 100 mg/ml for four 
hours and 50 mg/ml or 100mg/ml for 24 hours. There 
were no significant differences at one hour or with lower 
concentrations of TXA.
Cellular death. We subsequently measured mitochon­
drial membrane potential as a direct measure of cellular 
death (apoptosis, Fig. 3). Tenocyte apoptosis was signifi­
cantly increased when cells were treated with 100 mg/ ml 
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Control
Tenocyte FLS Chondrocyte
1 hr
4 hrs
Tranexamic acid (TXA)­associated periarticular apoptosis. Percentage of: a) and b) tenocyte (n = 3); c) and d) fibroblast­like synoviocyte (FlS; n = 3); and e) and 
f) chondrocyte (n = 4) death at a), c), e) one and b), d), f) four hours with 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml TXA treatment. Dying cells (green) were 
calculated as a proportion of healthy (red) cells. *p < 0.05; †p < 0.01. Data represent mean ± standard error of the mean; one­way analysis of variance; Dunnett’s 
Multiple Comparison Test. g) Fluorescent microscopy images show tenocytes, FlS, and chondrocytes at: one hour, 0 mg/ml TXA; one hour, 100 mg/ml TXA; and 
four hours, 100 mg/ml TXA.
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for one hour or 50 mg/ml to 100 mg/ml TXA for four 
hours. Fibroblast­like synoviocyte and chondrocyte cell 
apoptosis was significantly increased when cells were 
exposed to 50 mg/ml or 100 mg/ml for one hour and 
100 mg/ml for four hours.
Multi-protein apoptotic arrays. As fluorescent microscopy 
identified increased cell death at one and four hours, we 
carried out single­sample, multi­protein, apoptotic arrays 
to identify potential mechanisms that may be involved 
(Fig. 4). Treatment with 0 mg/ml, 1 mg/ml, 50 mg/ml, 
Fig. 4a
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a) Tranexamic acid (TXA)­associated periarticular apoptosis pathways. Caspase­3 activation induced by tranexamic acid in vitro in periarticular tissues: b) and c) 
tenocyte; d) and e) fibroblast­like synoviocyte (FlS); and f) and g) chondrocyte single­sample multi­protein apoptotic arrays. b), d), f) Pro caspase­3 and c), e), 
g) cleaved caspase­3 samples were treated with 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml of TXA for one hour. Pro and cleaved forms of caspase­3 signal 
pixel density plotted relative to control spots. HSP, heat shock protein; XIAP, X­linked inhibitor of apoptosis protein; cIAP, cellular inhibitor of apoptosis protein; 
Ho­1, heme oxygenase 1; HIF1­α, hypoxia­inducible factor 1­alpha.
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and 100 mg/ml of TXA for one hour caused an increase in 
apoptotic protein expression in tenocytes (pro caspase­3, 
cleaved caspase­3, Catalase, heat shock protein (HSP) 27, 
FlS cells (X­linked inhibitor of apoptosis protein (XIAP), 
Survivin, cellular inhibitor of apoptosis protein (cIAP), 
HSP27, Catalase, heme oxygenase 1 (Ho­1), HSP70 and 
HSP60, cleaved and pro caspase­3) and chondrocytes 
(Ho­2, Phosphorad­17, hypoxia­inducible factor 1­alpha 
(HIF1­α), cleaved and pro caspase­3). This suggests that 
TXA­mediated cell death may be orchestrated in part via 
a caspase­3­dependent apoptotic mechanism across all 
cell types.
Discussion
our study provides evidence of TXA cytotoxicity to 
human periarticular tissues ex vivo and in vitro at concen­
trations and durations of treatment routinely used in a 
clinical environment. Human tendon, synovium, and car­
tilage tissues all showed significantly higher rates of cell 
death when treated with TXA over a clinically relevant 
time period when considering the tissue half­life of TXA 
following Iv administration.6
The use of TXA as an intravenous haemostatic agent 
during hip and knee arthroplasty is well established, with 
proven benefits in reduction of peri­ and postoperative 
blood loss.3,6 Increasingly, its use is being expanded to 
topical application in orthopaedic surgical procedures,23­25 
which has been shown to deliver similar outcomes post­
operatively to those of intravenous administration.11,26­29 
Furthermore, its utilization has now expanded into topical 
application during soft­tissue surgery including arthro­
scopic ACl reconstruction.30,31 There are various methods 
of topical administration described in the literature, 
including, but not limited to, pre­ or postoperative injec­
tion, intraoperative wash, postoperative intra­ articular 
infusion through a surgical drain, and direct tissue impreg­
nation.11,28,29,32­36 Most literature describes the administra­
tion of between 10 mg/ml and 100 mg/ml of TXA; 
however, significantly larger doses have been reported.33 
Indeed, treatment with high­dose TXA (100 mg/ml) into 
tissues or a closed joint space may result in concentrations 
remaining within the synovial fluid and tissues36 of over 
1 mg/ml at up to 24 hours or longer. our findings sug­
gest that caution should be used when considering expos­
ing periarticular tissues to TXA either at high concentrations 
or for durations even as short as one hour. The practice of 
intra­articular injection or infusion, prolonged surgical 
soaking, or tissue impregnation, particularly when into an 
enclosed joint or space, should be undertaken with the 
knowledge of the current study and other studies that 
show increased cell death.
Previous studies investigating TXA cytotoxicity to resi­
dent periarticular tissues have produced variable results 
depending on animal versus human tissue and dosing 
regime utilized.13­17 Tuttle et al17 found that treatment 
with 100 mg/ml of TXA was cytotoxic to bovine cartilage 
explants, and 50 mg/ml to murine chondrocytes from as 
early as eight hours. Ambra et al14 treated porcine carti­
lage explants with 0 mg/ml to 4 mg/ml of TXA for up to 
six hours and found no significant increase in cytotoxic­
ity with live/dead cell staining and confocal microscopy. 
Sitek et al13 found no obvious effect on human chondro­
cyte culture within gel grafts when grown in culture 
media containing 10 mg/ml or 20 mg/ml of TXA. More 
recently, Parker et al16 described cytotoxicity in human 
chondrocytes in vivo and cartilage explants ex vivo at 
concentrations over 20 mg/ml at 12 hours’ exposure. 
We noted decreased cell viability in tenocytes, FlS, and 
chondrocytes when exposed to high concentrations 
(100 mg/ml) over an intermediate duration (four hours), 
but also even at the lowest concentration (1 mg/ml) 
over a longer duration (24 hours). Furthermore, our 
study directly addresses the mechanism underlying 
TXA­induced cell death whereby we implicate caspase­
dependent apoptosis.
There are limitations inherent in our study. None of 
our experiments take into account the TXA being washed 
away in vivo; the joint space is a dynamic environment 
and other cell types (e.g. inflammatory cells and plate­
lets) could potentially have a role in TXA clearance. We 
do, however, know that the half­life of TXA in a closed 
joint following intravenous administration is around 
three hours and thus we feel confident that our in vitro 
experiments are representative.
With our ex vivo model, we had a high percentage of 
cell death in our tendon control. This is likely due to the 
effect of tissue drying between surgical harvesting and 
completion of graft preparation. However, this may actu­
ally mask the true extent of TXA toxicity in tendon tissue. 
It may also have been beneficial to study the ex vivo effects 
of TXA at additional timepoints and TXA concentrations, 
as was carried out with our in vitro experimentation. In 
addition, we acknowledge that age­related degenerative 
changes may have had an influence on cell viability with 
regard to the synovium/cartilage obtained at THA/TKA, as 
they were from older patients but were constrained by 
our local ethics consent for obtaining tissue samples. 
While the current study shows increased cell death, this 
may not necessarily translate into poor clinical outcomes 
to the patient, and we recognize that studies evaluating 
early and longer­term clinical follow­up of topical TXA­
treated patients, particularly in soft­tissue orthopaedic 
surgery, should be undertaken in order to understand the 
translational potential of this basic science study.
on the basis of our findings, we would suggest that 
clinicians should show caution when considering topical 
TXA treatments, particularly on soft­tissue orthopaedic 
procedures. There is a need for further human clinical tri­
als in order to clarify the safety of this before it can be 
recommended for standard topical practice.
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